International journal of environmental research and public health · 2025
Health-Related Quality of Life and Functional Status of Post-COVID-19 Patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oliveira Miriã C, Alves Larissa R, Soares Juliana M P, Souza Shayra K A, Silva Bruna M R, Fonseca Adriano L, Silva Carlos H M, Oliveira Claudia S, Vieira Rodolfo P, Oliveira Deise A A P, Oliveira-Silva Iransé, Oliveira Rodrigo F, Sampaio Luciana M M, Maldaner Vinicius, Santos Dante B, Palma Renata K, Nacif Sergio R, Insalaco Giuseppe, Oliveira Luís V F
Аннотация
BACKGROUND: COVID-19 mainly affects the respiratory system, although its manifestations are multisystemic. We are increasingly recognizing complications that present after the acute phase, which are associated with impaired functional status and health-related quality of life (HRQoL). The objective was to assess the functional status and HRQoL of patients with post-COVID-19.
METHODS: This was a cross-sectional study involving individuals affected by COVID-19 who had persistent symptoms for one month after the acute phase of the disease. Functional status was measured with the six-minute walk test (6MWT), the Fatigue Severity Scale (FSS), the Medical Research Council (MRC) Dyspnea Scale, and the Post-COVID-19 Functional Status Scale (PCFS). HRQoL was confirmed with the Short-Form Health Survey 36 (SF-36).
RESULTS: We included 123 patients; 73 (59.35%) were male, with a mean age of 49.17 ± 13.48 years and a body mass index of 31.02 ± 6.56 stratified into three groups: the not-recovered group (NRG = 23), the ward-recovered group (WHG = 60), and the intensive-care-unit group (ICUG = 40). The main symptoms were muscle weakness (74.17%) and dyspnea (68.33%). The predicted distances for the 6MWT were missed by 12.83% by the GNR group, 20.21% by the GNR group, and 28.82% by the UGCI group. The MRC dyspnea scale had a mean value of less than 3, and the FSS scale had a mean value of over 4, indicating considerable fatigue. In the PCFS scale, a significant difference was observed (p < 0.0005), while in the SF-36, all HRQoL domains were compromised.
CONCLUSION: Post-COVID-19 patients involved in this study showed a significant decline in functional status and an impairment of HRQoL.
METHODS: This was a cross-sectional study involving individuals affected by COVID-19 who had persistent symptoms for one month after the acute phase of the disease. Functional status was measured with the six-minute walk test (6MWT), the Fatigue Severity Scale (FSS), the Medical Research Council (MRC) Dyspnea Scale, and the Post-COVID-19 Functional Status Scale (PCFS). HRQoL was confirmed with the Short-Form Health Survey 36 (SF-36).
RESULTS: We included 123 patients; 73 (59.35%) were male, with a mean age of 49.17 ± 13.48 years and a body mass index of 31.02 ± 6.56 stratified into three groups: the not-recovered group (NRG = 23), the ward-recovered group (WHG = 60), and the intensive-care-unit group (ICUG = 40). The main symptoms were muscle weakness (74.17%) and dyspnea (68.33%). The predicted distances for the 6MWT were missed by 12.83% by the GNR group, 20.21% by the GNR group, and 28.82% by the UGCI group. The MRC dyspnea scale had a mean value of less than 3, and the FSS scale had a mean value of over 4, indicating considerable fatigue. In the PCFS scale, a significant difference was observed (p < 0.0005), while in the SF-36, all HRQoL domains were compromised.
CONCLUSION: Post-COVID-19 patients involved in this study showed a significant decline in functional status and an impairment of HRQoL.